WO1992022815A1 - Support medium - Google Patents
Support medium Download PDFInfo
- Publication number
- WO1992022815A1 WO1992022815A1 PCT/GB1992/001118 GB9201118W WO9222815A1 WO 1992022815 A1 WO1992022815 A1 WO 1992022815A1 GB 9201118 W GB9201118 W GB 9201118W WO 9222815 A1 WO9222815 A1 WO 9222815A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- pores
- blinding
- sample
- bores
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/521—Single-layer analytical elements
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/805—Test papers
Definitions
- the present invention relates to a support medium, notably to a support medium for a blood analysis reagent.
- the analysis or testing of blood for the presence of glucose or other materials is carried out by applying a droplet of the blood to a test strip which carries a pad of a mixture of reagents which give a colour indication in response to one or more of the materials under test.
- the test strip typically carries the reagent(s) in a gelatin or other inert polymer or gel matrix pad at one end of a white plastic strip.
- the pores which are initially present in the membrane are blocked or blinded so that there is no free flow of fluid into the pores and the fluid component to be tested is separated by the membrane from cellular components of the material.
- the membrane can be mounted as an end wall of a chamber into which the blood is introduced for testing. The sample of blood is thus held enclosed within the chamber and the risk of external contamination and cross-contamination from other samples is reduced. Also, since the sample is retained within the chamber, the problems associated with disposal of the sample after testing are reduced.
- the present invention provides a membrane suitable for use as the support for one or more test reagents for testing a material applied to the membrane, and particularly for use in a back reading technique in which blood plasma is separated from blood cells in a sample of blood applied to one surface of the membrane and the response of a reagent carried by the membrane is observed from another surface of the membrane, which membrane is characterised in that initially it is an open pored porous material and in that at least part of the length the pores therein are blinded so that cell wall fragments are substantially prevented from passage through the membrane.
- At least 50%, eg more than 75%, of the length of the bores of the pores, notably substantially the whole length of the bores of the pores, are blinded and the blinding agent either substantially completely fills the cross- section of the bores or the bores are blocked to such an extent that the effective pore size of the membrane is reduced to a size below that at which rupture of the cell wall in the cellular component of the material applied to the membrane occurs to any significant extent.
- the membrane is a porous plastic sheet material, although other forms of membrane, for example a tube or other shaped member formed from or carrying the membrane can be used if desired.
- the membrane can be in the form of a conventional blood test stick.
- the invention is of especial application in a back read test method, notably one in which the membrane forms one wall of a container for the fluid sample, so that the sample is held within the container and is isolated from the en-u ⁇ ronment once it has been fed into the container.
- the membrane forms a means for separating the non-cellular fluid from any cellular components of the fluid to be tested, and which allows the non-cellular fluid to pass into the material blinding the pores of the membrane with reduced cell wall rupture.
- the membrane can be made from a wide range of materials having regard to the fluid to be applied to it, the size and nature of the cellular components therein and the test which is to be carried out on the non-cellular fluid component.
- the membrane will be a sheet of open pored porous plastic, notably one with an initial pore size which is smaller than the size of the cells which it is desired to separate out from the fluid.
- the membrane may be made from a wide range of polymeric materials, for example cellulose, nitrocellulose and other cellulose derivatives such as cellulose esters; spun or woven polyamide fibres; polyvinylidene polymers; polycarbonate polymers; polysulfone polymers; polyalkylene polymers; acrylic or methacrylic acid polymers or co-polymers; polyamide polymers; polytetra- fluorethylene polymers and the like.
- polymeric materials for example cellulose, nitrocellulose and other cellulose derivatives such as cellulose esters; spun or woven polyamide fibres; polyvinylidene polymers; polycarbonate polymers; polysulfone polymers; polyalkylene polymers; acrylic or methacrylic acid polymers or co-polymers; polyamide polymers; polytetra- fluorethylene polymers and the like.
- the polymer will typically be in sheet form, but it may contain fibrous or other reinforcement if desired; or may be in the form of fine weave aperture woven fabrics. Such sheet materials will usually be flexible and will require mounting on a support member or the like for use. However, it is within the scope of the present invention to use a membrane in a rigid form, for example a sintered frit or ceramic having tortuous interconnecting interstices therethrough footling the pores which are to be blinded according to the invention. For convenience, the invention will be described hereinafter in terms of a sheet polymer as the membrane.
- the pores can be formed within the membrane during its manufacture, as when a volatile material or a soluble salt or other material is incorporated into the polymers sheet, for example during calendering thereof, and this is subsequently evaporated or leached out of the polymer to leave a series of interconnecting passages or pores.
- the pores can be formed after manufacture of the sheet polymer, for example by needling or spark eroding the sheet polymer.
- the pores in the membrane will have a mean diameter of from 0.1 to 10 micrometres, preferably from 0.1 to l micrometres and the membrane will have an air permeability of from 1.5 to 4 litres per minute per square centimetre at an applied pressure of 10 psig across the plane of the membrane.
- Many forms of such membrane materials are available commercially and may be used in their commBrcially available form.
- the membrane is preferably sufficiently thick that the colour of any blood cells retained on the face to which the sample has been applied does not adversely affect the colour observed in the reagent with which the non-cellular components have interacted.
- the membrane will be from 50 to 500 micrometres thick so that excessive amounts of sample are not bound into the blinding material in the pore volume of the membrane.
- the pores of the membrane are at least partially blinded by a material so that the initial pore size is reduced to a level at which either' the surface ' tension effect at the entry to the pores is reduced to below that at which rupture of the cell wall is reduced and/or the pore is completely blocked by the blinding medium and thus does not cause rupture of the cells or does not allow the passage of significant amounts of cell wall fragments.
- the membrane can be padded in a fluid which carries solid particles suspended or dispersed therein or a colloidal solution of solid particles so that solid particles enter the pores and form a continuous mechanical blinding within the pores. In this case it may be desirable to apply a pre-coating to the pores to aid retention of the particles upon the walls of the pores.
- a thermoplastic or thermoset material can be used which is applied when molten, but which sets within the pores to form the blinding.
- the blinding agent may be one which sets in situ within the pores due to loss of water or due to a change in the rheological properties of the material, for example as when a fluid gels or a thixotropic material re-solidifies.
- the blinding material can be caused to set by a chemical change, as when a pre-polymer or monomer is caused to polymerise in situ.
- the material used to blind the bores of the pores is a material which readily wets the walls of the pores so as to reduce the formation of air pockets within the membrane; is a material which is inert to the reagents and the fluid to be tested; and preferably acts as a carrier for the reagents to be used in the test so as to form a translucent matrix within the bore so that the colour developed within the bore of the pore can be observed.
- the blinding agent will often act as the medium through which the products of the interaction of the material under assessment with one or more of the reagents in the matrix diffuse to interact with other components, for example a chromogen. It is therefore preferred that the blinding of the pores form a continuous solid or matrix body within the pore, rather than a plug of solid particles with fine interconnecting interstices throughout the plug, so that this diffusion may take place. This is particularly important where interaction between the fluid being assessed and an enzyme reagent takes place to release a product, for example hydrogen peroxide, which then reacts with another component, for example the chromogen o-tolidine, to give a colour which is observed from the exposed outer face of the membrane.
- a product for example hydrogen peroxide
- an aqueous solution or colloidal suspension of gelatin is used to form a gel plug within all or part of the length of the pore bores.
- the gelatin for present use preferably has a low or medium molecular weight, for example with an average molecular weight within the range 2,000 to 50,000.
- Such forms of gelatin are commercially available and may be used in their commercially avaiable forms.
- the commercial material can be subjected to a pre- treatment, for example acid washing or other conventional treatment, to render ⁇ z suitable for use in blood analysis or testing.
- the blinding of the pores can be carried out so that the whole length of each bore is blinded. However, this is often not necessary and blinding of only part of the length of the pore bores may give satisfactory results.
- the amount of blinding agent applied to a membrane will depend upon the pore diameter, the thickness of the membrane, the material to be tested and the nature of the test to be carried out. The optimum amount can readily be established by simple trial and error tests for any given case. However, where a gelatin blinding agent is used, we have found that the application of from 1 to 10, eg. 2 to 6, milligrams of gelatin per square metre of a 0.1 to 0.5 mm thick membrane will usually be required.
- the blinding is preferably carried out so as to blind the whole plan area of the membrane. However, it may be desired to provide the blinding to only a selected area of the membrane to which the blood or other material to be tested is applied. Alternatively, the membrane can be cut into discs or strips to provide the desired area of treated membrane.
- the blinding material can be applied to the membrane by any suitable method.
- a solution or suspension of the material can be applied by spraying dipping, roller coating or padding to the membrane so as to load the membrane with the desired amount of blinding material.
- the concentration of the gelatin in the total blinding mixture applied to the membrane can vary from about 400 parts by weight per 600 parts by volume of water or other carrier fluid for a gelatin having an average molecular weight of 2-3,000, to 100 parts by weight per 600 parts by volume of the carrier fluid for a gelatin having an average molecular weight in the range 25,000 to 40,000.
- the material can be assisted into the bores of the pores by applying suction to one face of the membrane to draw material into the pores and/or by applying a hydrostatic head to the membrane to force the blinding material into the pores.
- the membranes of the invention find especial use to support reagents for some test to be carried out on a fluid applied to the membrane.
- the membrane can support a surface coating of the reagents on that face opposed to the one to which the sample is applied so that the non-cellular fluid from the sample penetrates through the blinded pores and contacts the reagent layer.
- the reagents be incorporated in the blinding within the pores, for example by incorporating the appropriate reagents in an aqueous gel applied to the membrane, so that the non-cellular fluid interacts with the reagents in the pores of the membrane to provide a colouration to the blinding which can be observed from the other face of the membrane.
- the membranes of the invention can be used in a wide range of applications where it is desired to separate the non-cellular fluid from the cellular components of a fluid for testing.
- the membranes can be used in the assessment of plant cellular materials and the like.
- the invention is of especial application in testing blood or other bodily fluids, notably for the glucose, urea or cholesterol content thereof.
- Figure 1 is a diagrammatic sectional view through a membrane of the invention; and Figure 2 shows the membrane is use in a back reading technique testing device.
- a first solution was made by stirring together at room temperature 300 mis of de-ionised water, 200 mis of 0.5 Molar sodium phosphate buffer to give a pH of 7, 100 mis of a 20% w/v solution of the surfactant Gantrez and 300 gs of dry powdered gelatin having a molecular weight in the range 25,000 to 40,000.
- a second solution was prepared by stirring together at 60° c for one hour 300 mis of de-ionised water, 300 mis of methoxyethanol and 15 gs of o-tolidine hydrochloride or dianisidine hydrochloride.
- the second solution was mixed dropwise with stirring into the first solution and the mixture stood for 1 hour at 60° C.
- a third solution was made up by mixing 500,000 I ⁇ s. of glucose oxidase and 30,000 IUs of peroxidase in 0.1 Molax solution of the sodium phosphate buffer. This solution was mixed with stirring into the other mixed solutions and filtered through a 0.1 micrometre aperture filter.
- the resultant solution was impregnated into a polys ⁇ lfone resin sheet 1 (0.2 to 0.4 rams thick and having a pore diameter of 0.2 micrometres and an air permeability of 3 litres per minute per square centimetre at an applied pressure of 10 psig) to provide 5 IUs of glucose oxidase, 3 IUs of peroxidase, 0.2 milligrams of o-tolidine and 4 milligrams of gelatin per square centimetre of the membrane 1.
- the impregantion was carried out by padding the membrane sheet through the aqueous solution. Since the polysulfone resin is hydrophylic, the gelatin solution wets the internal surfaces of the pores and the capillary action of the pores readily ensures that the gelatin solution enters the pores.
- the padding is carried out first with the membrane one way up until the solution wets the upper surface of the membrane, then the other way up so that the pores 2 are substantially filled with the gelatin solution.
- the loaded membrane is allowed to dry so that a solid plug 3 of the gelatin gel is formed within the pores.
- the membrane is cut into discs 10 which are used to form the end wall of a test chamber 11 having an open top or bore 12 into which a drop of blood 13 can be fed.
- the blood enters the chamber 11 so that it is held wholly within the test device 14.
- the blood 13 wets the inner face of the membrane and the non- cellular plasma penetrates the pores 2 by absorption or solution in the gelatin plug 3.
- the blood cells are prevented from entering the pores by the gelatin plug and little or no rupture of the blood cells occurs.
- the membrane of the invention reduces the rupture of the blood cells and thus reduces the colouration observation errors due to blood cell fragments.
- the present invention thus provides a method for testing blood, which method comprises applying a sample of the blood to a first surface of an initially porous membrane, which membrane carries a gelatin based matrix containing at least one reagent to respond to a component in the blood therein, the said matrix substantially completely blinding the pores in the membrane in the area to which the said sample is applied, whereby red blood cells in the said sample are retained substantially unruptured at said first surface and the plasma of the said sample passes into the said matrix to interact with said reagent to produce a colour; and observing the colour from a second surface of said membrane.
- the invention also provides a method for producing a membrane of the invention, which method comprises applying a fluid composition containing a blinding material to an initially porous membrane whereby the fluid penetrates the bores of the pores of the membrane; and allowing the composition to solidify so as to form a solid within the said pores which substantially completely occupies at least part of the length of the bores of the pores.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20213/92A AU668353B2 (en) | 1991-06-19 | 1992-06-19 | Support medium |
DE69219601T DE69219601T2 (en) | 1991-06-19 | 1992-06-19 | A porous membrane suitable for determining a component contained in a biological fluid |
EP92913028A EP0591315B1 (en) | 1991-06-19 | 1992-06-19 | A porous membrane suitable for testing for the presence of a component in a biological fluid sample |
JP50080193A JP3172184B2 (en) | 1991-06-19 | 1992-06-19 | Support medium |
GR970402019T GR3024372T3 (en) | 1991-06-19 | 1997-08-06 | Support medium |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9113211.8 | 1991-06-19 | ||
GB919113211A GB9113211D0 (en) | 1991-06-19 | 1991-06-19 | Support membrane |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992022815A1 true WO1992022815A1 (en) | 1992-12-23 |
Family
ID=10696931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1992/001118 WO1992022815A1 (en) | 1991-06-19 | 1992-06-19 | Support medium |
Country Status (12)
Country | Link |
---|---|
US (1) | US5494638A (en) |
EP (1) | EP0591315B1 (en) |
JP (1) | JP3172184B2 (en) |
AT (1) | ATE152833T1 (en) |
AU (1) | AU668353B2 (en) |
CA (1) | CA2110909A1 (en) |
DE (1) | DE69219601T2 (en) |
ES (1) | ES2103950T3 (en) |
GB (1) | GB9113211D0 (en) |
GR (1) | GR3024372T3 (en) |
HU (1) | HU217217B (en) |
WO (1) | WO1992022815A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2326476A (en) * | 1997-06-17 | 1998-12-23 | Hypoguard | Reagent comprising polymeric binder, chromogen, catalyst system which initiates colour change, and sulphonate or buffer |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232124B1 (en) | 1996-05-06 | 2001-05-15 | Verification Technologies, Inc. | Automated fingerprint methods and chemistry for product authentication and monitoring |
JP3699799B2 (en) * | 1997-03-11 | 2005-09-28 | テルモ株式会社 | Blood test tool |
US7390667B2 (en) * | 1997-12-22 | 2008-06-24 | Roche Diagnostics Operations, Inc. | System and method for analyte measurement using AC phase angle measurements |
US8071384B2 (en) | 1997-12-22 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Control and calibration solutions and methods for their use |
US6490030B1 (en) | 1999-01-18 | 2002-12-03 | Verification Technologies, Inc. | Portable product authentication device |
US20050103624A1 (en) * | 1999-10-04 | 2005-05-19 | Bhullar Raghbir S. | Biosensor and method of making |
US6512580B1 (en) | 1999-10-27 | 2003-01-28 | Verification Technologies, Inc. | Method and apparatus for portable product authentication |
US20030112423A1 (en) * | 2000-04-24 | 2003-06-19 | Rakesh Vig | On-line verification of an authentication mark applied to products or product packaging |
US20040000787A1 (en) * | 2000-04-24 | 2004-01-01 | Rakesh Vig | Authentication mark for a product or product package |
US6638593B2 (en) | 2000-06-30 | 2003-10-28 | Verification Technologies, Inc. | Copy-protected optical media and method of manufacture thereof |
US7124944B2 (en) * | 2000-06-30 | 2006-10-24 | Verification Technologies, Inc. | Product packaging including digital data |
WO2002002301A1 (en) | 2000-06-30 | 2002-01-10 | Verification Technologies Inc. | Copy-protected optical media and method of manufacture thereof |
US7660415B2 (en) * | 2000-08-03 | 2010-02-09 | Selinfreund Richard H | Method and apparatus for controlling access to storage media |
US20060006141A1 (en) * | 2001-11-16 | 2006-01-12 | Stefan Ufer | Biomedical electrochemical sensor array and method of fabrication |
US20050084645A1 (en) * | 2002-02-07 | 2005-04-21 | Selinfreund Richard H. | Method and system for optical disc copy-protection |
US20040023397A1 (en) * | 2002-08-05 | 2004-02-05 | Rakesh Vig | Tamper-resistant authentication mark for use in product or product packaging authentication |
MXPA05003218A (en) * | 2002-09-26 | 2005-09-12 | Verification Technologies Inc | Authentication of items using transient optical state change materials. |
US20060203700A1 (en) * | 2003-02-06 | 2006-09-14 | Verification Technologies, Inc. | Method and system for optical disk copy-protection |
US7645421B2 (en) * | 2003-06-20 | 2010-01-12 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
US8058077B2 (en) | 2003-06-20 | 2011-11-15 | Roche Diagnostics Operations, Inc. | Method for coding information on a biosensor test strip |
US8679853B2 (en) * | 2003-06-20 | 2014-03-25 | Roche Diagnostics Operations, Inc. | Biosensor with laser-sealed capillary space and method of making |
PL1642117T3 (en) | 2003-06-20 | 2018-11-30 | F.Hoffmann-La Roche Ag | Reagent stripe for test strip |
US7488601B2 (en) | 2003-06-20 | 2009-02-10 | Roche Diagnostic Operations, Inc. | System and method for determining an abused sensor during analyte measurement |
US8206565B2 (en) | 2003-06-20 | 2012-06-26 | Roche Diagnostics Operation, Inc. | System and method for coding information on a biosensor test strip |
US8148164B2 (en) * | 2003-06-20 | 2012-04-03 | Roche Diagnostics Operations, Inc. | System and method for determining the concentration of an analyte in a sample fluid |
US7452457B2 (en) * | 2003-06-20 | 2008-11-18 | Roche Diagnostics Operations, Inc. | System and method for analyte measurement using dose sufficiency electrodes |
US7645373B2 (en) * | 2003-06-20 | 2010-01-12 | Roche Diagnostic Operations, Inc. | System and method for coding information on a biosensor test strip |
US7597793B2 (en) * | 2003-06-20 | 2009-10-06 | Roche Operations Ltd. | System and method for analyte measurement employing maximum dosing time delay |
US8071030B2 (en) * | 2003-06-20 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Test strip with flared sample receiving chamber |
US7718439B2 (en) | 2003-06-20 | 2010-05-18 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
WO2005078118A1 (en) | 2004-02-06 | 2005-08-25 | Bayer Healthcare Llc | Oxidizable species as an internal reference for biosensors and method of use |
US7556723B2 (en) * | 2004-06-18 | 2009-07-07 | Roche Diagnostics Operations, Inc. | Electrode design for biosensor |
US7569126B2 (en) | 2004-06-18 | 2009-08-04 | Roche Diagnostics Operations, Inc. | System and method for quality assurance of a biosensor test strip |
DE102004046618A1 (en) * | 2004-09-25 | 2006-03-30 | Robert Bosch Gmbh | Circuit arrangement for analog / digital conversion |
KR101503072B1 (en) | 2005-07-20 | 2015-03-16 | 바이엘 헬스케어 엘엘씨 | Gated amperometry |
KR101577176B1 (en) | 2005-09-30 | 2015-12-14 | 바이엘 헬스케어 엘엘씨 | Gated voltammetry analyte determination |
WO2009076302A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and methods of use |
JP6782218B2 (en) * | 2017-11-17 | 2020-11-11 | 株式会社東芝 | Detection device and detection method |
JP7050878B2 (en) * | 2020-10-09 | 2022-04-08 | 株式会社東芝 | Detection device and detection method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0256806A2 (en) * | 1986-08-13 | 1988-02-24 | Lifescan, Inc. | Method for the determination of glucose in whole blood |
EP0265253A2 (en) * | 1986-10-24 | 1988-04-27 | Kingston Technologies, Inc. | Stabilized dispersed enzyme |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3811840A (en) * | 1969-04-01 | 1974-05-21 | Miles Lab | Test device for detecting low concentrations of substances in fluids |
DE3407359A1 (en) * | 1984-02-29 | 1985-08-29 | Bayer Ag, 5090 Leverkusen | TEST DEVICE AND METHOD FOR DETECTING A COMPONENT OF A LIQUID SAMPLE |
JPS614959A (en) * | 1984-06-19 | 1986-01-10 | Fuji Photo Film Co Ltd | Monolithic type multi-layered analyzing element |
DE3681663D1 (en) * | 1985-03-06 | 1991-10-31 | Memtec Ltd | CHANGE IN PORE SIZE DISTRIBUTION. |
US5059394A (en) * | 1986-08-13 | 1991-10-22 | Lifescan, Inc. | Analytical device for the automated determination of analytes in fluids |
US5049487A (en) * | 1986-08-13 | 1991-09-17 | Lifescan, Inc. | Automated initiation of timing of reflectance readings |
GB8620484D0 (en) * | 1986-08-22 | 1986-10-01 | Raychem Ltd | Plugged microporous film |
DE4015157A1 (en) * | 1990-05-11 | 1991-11-14 | Miles Inc | ASYMETRIC SANDWICH MEMBRANES FOR DIAGNOSTIC TEST STRIPS |
-
1991
- 1991-06-19 GB GB919113211A patent/GB9113211D0/en active Pending
-
1992
- 1992-06-19 WO PCT/GB1992/001118 patent/WO1992022815A1/en active IP Right Grant
- 1992-06-19 JP JP50080193A patent/JP3172184B2/en not_active Expired - Fee Related
- 1992-06-19 ES ES92913028T patent/ES2103950T3/en not_active Expired - Lifetime
- 1992-06-19 AT AT92913028T patent/ATE152833T1/en not_active IP Right Cessation
- 1992-06-19 EP EP92913028A patent/EP0591315B1/en not_active Expired - Lifetime
- 1992-06-19 CA CA002110909A patent/CA2110909A1/en not_active Abandoned
- 1992-06-19 DE DE69219601T patent/DE69219601T2/en not_active Expired - Fee Related
- 1992-06-19 AU AU20213/92A patent/AU668353B2/en not_active Ceased
- 1992-06-19 HU HU9303641A patent/HU217217B/en not_active IP Right Cessation
-
1994
- 1994-09-23 US US08/311,713 patent/US5494638A/en not_active Expired - Lifetime
-
1997
- 1997-08-06 GR GR970402019T patent/GR3024372T3/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0256806A2 (en) * | 1986-08-13 | 1988-02-24 | Lifescan, Inc. | Method for the determination of glucose in whole blood |
EP0265253A2 (en) * | 1986-10-24 | 1988-04-27 | Kingston Technologies, Inc. | Stabilized dispersed enzyme |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2326476A (en) * | 1997-06-17 | 1998-12-23 | Hypoguard | Reagent comprising polymeric binder, chromogen, catalyst system which initiates colour change, and sulphonate or buffer |
Also Published As
Publication number | Publication date |
---|---|
GR3024372T3 (en) | 1997-11-28 |
ES2103950T3 (en) | 1997-10-01 |
HU217217B (en) | 1999-12-28 |
US5494638A (en) | 1996-02-27 |
AU2021392A (en) | 1993-01-12 |
EP0591315B1 (en) | 1997-05-07 |
EP0591315A1 (en) | 1994-04-13 |
AU668353B2 (en) | 1996-05-02 |
HUT69377A (en) | 1995-09-28 |
CA2110909A1 (en) | 1992-12-23 |
JP3172184B2 (en) | 2001-06-04 |
DE69219601T2 (en) | 1997-12-04 |
GB9113211D0 (en) | 1991-08-07 |
DE69219601D1 (en) | 1997-06-12 |
ATE152833T1 (en) | 1997-05-15 |
JPH06508438A (en) | 1994-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0591315B1 (en) | A porous membrane suitable for testing for the presence of a component in a biological fluid sample | |
US4438067A (en) | Test strips for analyzing dissolved substances | |
US4292272A (en) | Multilayer analysis sheet for analyzing liquid samples | |
CA2014119C (en) | Methods and devices for the separation of plasma or serum from whole blood, collection of plasma or serum, and reagent delivery system | |
US4906439A (en) | Biological diagnostic device and method of use | |
CA1177374A (en) | Process and agent for separating plasma or serum from whole blood | |
US4307195A (en) | Immobilized enzyme membrane | |
JPH03163361A (en) | Blood separation and detection of assay product | |
EP0322669B1 (en) | Dry liquid analysis element | |
JPH0417388B2 (en) | ||
JPS60209174A (en) | Test apparatus and method for detecting component of liquid sample | |
WO1998020348A1 (en) | Opaque reaction matrix for the analysis of whole blood | |
EP0698413A2 (en) | Biological fluid analyzing device and method | |
EP0408223B1 (en) | Device and method for separation of plasma from blood and determination of blood analytes | |
US4594224A (en) | Analytical element | |
CA2179593A1 (en) | Multilayer analytical element for the determination of an analyte in a liquid | |
US4340565A (en) | Hematocrit value determining element | |
EP0226465A2 (en) | Integral multilayer analytical element | |
EP0408222A1 (en) | Device and method for separation of fluid components | |
US4540670A (en) | Method for measurement of liquid samples | |
JPH06504376A (en) | Test carrier for measuring analytes in whole blood | |
AU592771B2 (en) | Device composed of polymers with a membrane structure and incorporated solids particles | |
AU670882B2 (en) | Analyte detection device and process | |
WO1992022814A1 (en) | Support medium | |
DE102004058794A1 (en) | Process for coating membranes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2110909 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992913028 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992913028 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992913028 Country of ref document: EP |